Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.57 |
| ▸ | GSPT1 | P15170 | 4/20 | 0.57 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.57 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | IKZF2 | Q9UKS7 | 10/20 | 0.44 |
| ▸ | CSNK1A1 | P48729 | 4/20 | 0.43 |
| ▸ | WIZ | O95785 | 1/20 | 0.42 |
| ▸ | F11 | P03951 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20496778 | 1.00 | CRBN (0.57) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL20496750 | 0.90 | CRBN (0.71) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL20496751 | 0.90 | CRBN (0.71) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL20496763 | 0.89 | CRBN (0.74) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL20496764 | 0.89 | CRBN (0.74) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL20496752 | 0.86 | CRBN (0.60) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL20496753 | 0.86 | CRBN (0.60) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL1413529 | 0.85 | CRBN (0.66) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL20496834 | 0.85 | CRBN (0.59) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL20496832 | 0.85 | CRBN (0.59) | CRBNGSPT1DDB1IKZF3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10857155-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10857155-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10406165-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-10406165-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180264000-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2018-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180264000-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | GSPT1, GSPT2, GGT1 | CRBN 1138/4885GSPT1 1/4885DDB1 572/4885 |
| US-10857155-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | GSPT1, GSPT2, GGT1 | CRBN 1138/4885GSPT1 1/4885DDB1 572/4885 |
| US-10406165-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | GSPT1, GSPT2, GGT1 | CRBN 1138/4885GSPT1 1/4885DDB1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.